Identification of novel molecular subtypes to improve the classification framework of nasopharyngeal carcinoma.

ABSTRACT:

Background

Nasopharyngeal carcinoma (NPC) treatment is largely based on a 'one-drug-fits-all' strategy in patients with similar pathological characteristics. However, given its biological heterogeneity, patients at the same clinical stage or similar therapies exhibit significant clinical differences. Thus, novel molecular subgroups based on these characteristics may better therapeutic outcomes.

Methods

Herein, 192 treatment-naïve NPC samples with corresponding clinicopathological information were obtained from Fujian Cancer Hospital between January 2015 and January 2018. The gene expression profiles of the samples were obtained by RNA sequencing. Molecular subtypes were identified by consensus clustering. External NPC cohorts were used as the validation sets.

Results

SUBMITTER: Lin W 

PROVIDER: S-EPMC10991292 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature